Targeted Diagnosis and Therapy

Kereos, Inc. develops targeted molecular imaging agents and therapeutics designed to detect and treat cancer and cardiovascular disease earlier and more specifically than currently possible.

The specificity and unique capabilities of Kereos' molecular imaging agents enable earlier and more definitive diagnosis of disease.

Similarly, Kereos' targeted therapeutics seek out definitive disease biomarkers; making them potentially more effective and less toxic in treating disease.

With its lead candidates projected to enter the clinic in 2010, Kereos is at the forefront of bringing targeted molecular imaging and therapy to patients. Kereos is committed to developing its pipeline of products to address the unmet medical needs associated with America's top two killers.

Kereos has exclusively licensed the ligand-targeted emulsion candidates and underlying technologies from the Washington University School of Medicine/Barnes-Jewish Hospital (WU/BJH). Kereos and WU/BJH are collaborating on the development of these products, and the discovery of future candidates in the labs of Drs. Lanza and Wickline.